Investor Presentation - Q4 & FY26
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Windlas Biotech reported its highest-ever annual revenue of Rs 904 Cr for FY26, up 19% YoY, with Q4 FY26 revenue of Rs 238 Cr marking the 13th consecutive quarter of record revenue. Adjusted EBITDA grew 26% to Rs 121 Cr (13.4% margin) and adjusted PAT rose 31% to Rs 83 Cr (9.2% margin), with EPS at Rs 31.60. The company completed a Rs 47 Cr buyback in April 2026 without promoter participation and proposed a dividend of Rs 13 Cr. Strong cash generation of Rs 105 Cr resulted in net liquidity of Rs 251 Cr, keeping the company net debt free. Plant-6 has achieved mechanical completion and is on track for commercialization in H1 FY27.
Strong financial performance with margin expansion and healthy cash flows positions the company well for continued growth. The completed buyback and dividend proposal demonstrate commitment to shareholder returns while maintaining balance sheet strength.